The Mississauga fundraiser is among 22 ALS Canada fundraising walks across Ontario, which aim to raise $2 million.

The Everylife Foundation for Rare Diseases is offering a new scholarship for U.S. students from the ALS community facing ...

Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in ...

The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

House Bill 46, introduced by Rep. Ken King, expands Texas' medical marijuana program by adding allowing eligibility to more ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Despite its growing role in tracking MS activity, serum neurofilament light chain lacks diagnostic specificity, experts say.

ALS cases have been steadily rising in the United States for about the past decade, prompting new reporting requirements in Michigan.